Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation
Clinical and Molecular Hepatology · 01.07.2026 · 32 (3) · 1186-1200
DOI: 10.3350/cmh.2026.0697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2026. Verfasst von Gi-Ae Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Practice Guidelines as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Patient-Centered Clinical Research Coordinating Center, Ministry of Health and Welfare.
Abstract (Originalsprache)
International and regional clinical practice guidelines (CPGs) for chronic hepatitis B (CHB) have recently been updated to incorporate evolving clinical evidence. This review compares the latest major CPGs regarding natural history classification, treatment initiation, and selection of antiviral agents, specifically focusing on updates from the Korean Association for the Study of the Liver-East Asia Liver Alliance (KASL-EALA), the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the World Health Organization (WHO). While all guidelines recognize the heterogeneous and dynamic nature of CHB, managing patients in the “grey zone” or indeterminate phase remains a major challenge. The KASL–EALA 2026 guideline introduces a novel framework based primarily on hepatitis B virus (HBV) DNA levels—independent of alanine aminotransferase criteria—eliminating the indeterminate category to better align with hepatocellular carcinoma risks and simplify treatment decision-making. In contrast, AASLD 2025, EASL 2025, and WHO 2024 retain conventional immunological phase-based classifications for natural history. For treatment indications, all four guidelines advocate broader access to antiviral therapy despite their divergent structural approaches. AASLD suggests shared decision-making, EASL emphasizes individualized risk assessment, and WHO 2024 abandons the phase-based framework for treatment decisions entirely. Understanding these key similarities and differences will help clinicians optimize patient care and inform future efforts toward global harmonization in CHB management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea.
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University College of Medicine, Jeonju, Korea.
- Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Chiba, Japan.
- Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Förderung
- Patient-Centered Clinical Research Coordinating Center
- Ministry of Health and Welfare
Zitieren
APA
Kim, G. A., Choi, W. M., Choi, G. H., Kim, I. H., Kanto, T., Yu, M. L., & Lim, Y. S. (2026). Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation. Clinical and Molecular Hepatology, 32(3), 1186-1200. https://doi.org/10.3350/cmh.2026.0697
Vancouver
Kim GA, Choi WM, Choi GH, Kim IH, Kanto T, Yu ML, et al. Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation. Clinical and Molecular Hepatology. 2026;32(3):1186-1200. doi:10.3350/cmh.2026.0697
BibTeX
@article{Kim2026,
author = {Kim, Gi-Ae and Choi, Won-Mook and Choi, Gwang Hyeon and Kim, In Hee and Kanto, Tatsuya and Yu, Ming-Lung and Lim, Young-Suk},
title = {Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {3},
pages = {1186--1200},
doi = {10.3350/cmh.2026.0697}
}
EUVIMED